Traditional Landscape of Cystic Fibrosis Airway Infections: the Classics
Microbial proliferation in the CF airways, as a consequence of dysfunctional mucociliary
clearance, is dynamic with inhaled and aspirated microbes immigrating to the lower
airways where they have the opportunity to adapt to the surrounding microenvironment,
compete with resident microflora, where they may progress to chronic airway infections
([Fig. 1]).[7]
[8]
[9] In turn, these chronic airway infections lead to persistent host inflammation which
then potentiates a vicious cycle of structural lung damage, airflow obstruction, and
remodeling, and deteriorating respiratory function. In the absence of life-saving
lung transplantation, progressive respiratory disease is the leading cause of death
among pwCF.[10]
[11]
[12] The historic view of CF airways was one of evolution through age and disease-stage
with the characteristic presence of Haemophilus influenzae and Staphylococcus aureus during infancy and early childhood, eventually supplanted by Gram-negative bacteria,
including Pseudomonas aeruginosa and the Burkholderia cepacia complex ([Fig. 2]).[2]
[13] These classic pathogens have long been considered as hallmarks of progressive lung
disease—where they increase in prevalence and abundance with advancing disease severity
and their presence is associated with accelerated lung function decline.[14] The eventual domination of airway communities by these classical pathogens (acquired
from either natural environments or patient-patient spread) is postulated to be driven
in part by recurrent and frequent antibiotic exposure in response to acute PEx.[15]
[16]
[17] However, as we will explore further in this review, the evolving landscape of airway
microbiology created through intense study has offered new insight into these complex
communities ([Fig. 3]). Importantly, our review of each individual pathogen is by necessity general—and
the reader is directed to several detailed reviews for further reading.[15]
[18]
[19]
[20]
[21]
[22]
[23]
Fig. 1 Microbiology of the Cystic Fibrosis Airways. Microaspirated microbiota shapes early
colonizing communities through a balance of microbial immigration (movement of microbes into a new environment), growth and reproduction (influenced by factors for regional growth conditions including: (1) environmental
(i.e., nutrient availability, temperature, pH, and oxygen tension); (2) host (i.e.,
concentration and activation of inflammatory cells); and (3) bacterial (i.e., local
microbial composition/competition) and subsequent elimination (movement of microbes out of an environment (i.e. through cough and adjunctive airways
clearance measures, antimicrobial therapies, and host immune defenses]). In CF microbial
elimination, as a function of mucociliary clearance and host defense is critically
impaired. Classic pathogens that infect CF airways include Staphylococcus aureus (Sa), Pseudomonas aeruginosa (Pa), the Burkholderia cepacia complex (Bcc), Haemophilus influenzae (Hi), Stenotrophomonas maltophilia (Sm), and Achromobacter spp (Ax). Nonclassical taxa such as anaerobes and oropharyngeal flora (OF) also reside
within the microbiome. Development of aggregates and polymicrobial biofilms contribute
to longevity of chronic infections and antimicrobial resistance. Microbe–microbe interactions
within this community are numerous with examples including synergy (blue arrows, i.e,
upregulation of pathogen virulence by otherwise commensal bacteria) and inhibition
(red dashed lines, i.e., competition and growth inhibition of S. aureus by P. aeruginosa). Taken together, this complex milieu contributes to the upregulation of host proinflammatory
mechanisms and perpetuates vicious cycles of inflammation and infection. Figure created
with BioRender.
Fig. 2 Epidemiology of cystic fibrosis airways pathogens—a global perspective. (A) Overall prevalence of classical pathogens by any positive culture in 2020 as reported
by patient registry data from the United Kingdom,[211] Canada,[212] Australia,[213] Ireland,[214] and the United States.[215] (B) Prevalence (y-axis) of CF pathogens by any positive culture stratified by age groups
(x-axis) by country. Minor corrections for age ranges were made in order to compare
to other regions. All data were used with permission by each respective CF registry.
Fig. 3 Depictions of microbial concepts in the CF airway. (A) Within CF airways, organisms can cause infection (i.e., microorganism that directly or indirectly causes or can cause, disease) or
colonization (i.e., microbes that reside within the lung without causing harm). (B) Pathogens in CF airways can be viewed as classic (i.e., well-established organisms that cause CF progression and are tracked in national
registries) or emerging (i.e., microorganisms not traditionally associated with CF,
increasingly being recovered). (C) The natural history of infection—in particular with P. aeruginosa—includes both acute (i.e., acquisition of intermittent unique strains) and the eventual development of chronic (i.e., persistence of one P. aeruginosa strain, often associated with mucoid conversion) status. (D) Antibiotics can be used to achieve eradication (i.e., early and intensive use of antibiotics in response to a newly identified pathogen
to eliminate it from airways, thus preventing or delaying the establishment of chronic
infection) or suppression (i.e., intermittent use to alleviate or control symptoms rather than eliminate chronic
infection—which is not possible once established). (E) Strains of P. aeruginosa may be unique (i.e., those acquired through environmental exposures and not shared among other
individuals) and/or epidemic (i.e., a clonal strain that exists among a local CF population at a high prevalence
and has been conclusively demonstrated to be spread from CF person-to-person). Figure
created with BioRender.
Staphylococcus aureus
S. aureus, a gram positive, is often the earliest cultured pathogen in pwCF and reaches its
highest prevalence relatively early in life (50% of infants less than 2 years of age
and up to 80% in early adolescence).[24]
[25] Acquisition of S. aureus early in life is often attributed to high nasal colonization, estimated to be up
to 30% in the general population.[25]
S. aureus has recently become the most prevalent pathogen in pwCF due to a number of factors
including the efficacy of early eradication interventions directed against other pathogens.
Ecological pressure including regions of relative hypoxia secondary to mucus plugging,
host immune defenses, availability of nutrients, antibiotic therapy, and competition
with other pathogens results in the need for rapid adaptation to enable survival.
Such mechanisms include aggregate and biofilm formation,[26] in which both host immune response (i.e., host antibodies and macrophages) and antibacterial
therapy poorly penetrate, thereby ensuring persistence.[27] Infection with S. aureus has adverse clinical outcomes including a greater degree of airway inflammation and
lower lung function.[28]
[29]
[30]
[31] Given the importance of this pathogen in younger pwCF, prophylactic therapy followed
by suppressive strategies following acquisition with narrow-spectrum anti-Staphylococcal therapies has been assessed in multiple contexts,[32]
[33]
[34]
[35] but its routine use is regionally dependent.
Methicillin-resistant S. aureus (MRSA) emerged shortly after the introduction of methicillin as a semisynthetic penicillinase-resistant
antibiotic in the 1960s.[25] The MRSA phenotype results from the horizonal gene transfer of mecA, encoding the alternative penicillin-binding protein-2a which has low affinity for
methicillin and the isoxazolyl penicillins (and by inference all other beta-lactams,
other than the fifth generation cephalosporins).[36] While in the minority compared to methicillin-sensitive S. aureus (MSSA), the prevalence of MRSA ranges from 10 to 25% of pwCF globally—but with significant
variation by country ([Fig. 2]). MRSA infection is of particular clinical concern as its presence is associated
with accelerated lung function decline[37] and excess-associated mortality.[24]
[38]
[39]
S. aureus phenotypic divergence has been shown to influence clinical outcomes. Small colony
variant (SCV) transformation is another such adaptation disproportionate in CF that
is characterized by mutations in metabolic genes causing nutritional growth deficiencies
(making their identification in the laboratory more challenging) but conferring a
survival advantage including resistance to antibiotic pressure and host defenses.
SCVs are prevalent (found in 8.1-24% of pwCF) and disproportionally observed in higher
numbers among MRSA—attributed to higher sulfonamide treatments.[40] SCVs add a further layer of complexity for clinicians as they are frequently found
within host cells and are thereby relatively protected from the effects of many antibiotics—making
management difficult ([Table 1]).[41]
[42]
[43] Consequently, SCVs have been associated with chronic infection, worse lung function,
antibiotic resistance, and proliferation in the presence of other pathogens including
P. aeruginosa.[42]
[44]
[45]
[46] Notably, in a recent large multicenter-longitudinal study of CF children, across
multivariate models including P. aeruginosa and MRSA, only SCVs were consistently associated with worse clinical outcomes.[40]
Table 1
Commonly used antibacterial drugs and their relative spectrum of activity against
classical CF pathogens[a]
|
|
Abbreviations: A, Achromobacter. spp.; Bcc, Burkholderia cepacia complex; Hi, Haemophilus influenzae; MRSA, Methicillin-resistant Staphylococcus aureus; MSSA, Methicillin-sensitive Staphylococcus aureus; Pa, Pseudomonas aeruginosa; SCV, small-colony variant; Sm, Stenotrophomonas maltophilia.
a Drugs are organized by class and activity is inferred from multiple references.[48]
[97]
[215]
b Refers to regular growth.
c Agent with extensive bioavailability with oral route generally preferred.
The role of chronic MSSA prophylaxis and/or suppression is unclear with a lack of
consensus around whether prevention of colonization is an effective and safe measure
to reduce the acquisition of early lung infection. Indeed, a Cochrane review found
that while fewer children were positive for S. aureus when commenced with therapy early in infancy, the clinical impact was unclear with
no significant differences in lung function, hospital admissions, or nutrition when
compared to those without prophylaxis.[33] Moreover, given the association with an increased prevalence of P. aeruginosa following chronic suppressive anti-staphylococcal therapy,[32]
[47] the U.S. CF Foundation guidelines recommend against its routine use.[48] In contrast, given the disproportionate impact of chronic MRSA on CF clinical outcomes,
eradication attempts may be warranted to prevent persistent infection. Two placebo-controlled
randomized trials have been conducted to evaluate the efficacy of MRSA early eradication
using decolonization protocols (nasal, skin, and/or oral) with mupirocin/chlorhexidine
and 14 to 21 days of systemic trimethoprim-sulfamethoxazole in combination with rifampin
(with alternate regimens allowed in the case of resistance or intolerance). Muhlebach
and colleagues used a 14-day antibiotic protocol and showed significantly lower MRSA
positivity in the treated (26%) compared to the placebo (82%) arm at the primary endpoint
of 28 days (p < 0.001).[49] Moreover, this effect was sustained with 54% of subjects in the MRSA-negative treatment
arm after 12 weeks, compared to 10% in the control group. In contrast, Neri et al
identified a trend that did not meet significance, in the prevalence of chronic MRSA
negativity (defined as three negative cultures) between treated and control arms after
6 months.[50] Taken further, the Persistent MRSA Eradication Protocol was a randomized-control
trial evaluating a cohort of 29 adult pwCF with chronic (rather than new MRSA) colonization
to evaluate the potential of nebulized vancomycin or placebo in addition to oral antibiotics
(rifampin and trimethoprim/sulfamethoxazole or doxycycline) at clearing infection.[51]
[52] There were no significant differences in MRSA culture negativity at 1 or 3 months,
lung function, symptom scores, or absolute density of MRSA between those receiving
nebulized vancomycin or placebo.[52] Finally, a Cochrane systematic review evaluating the evidence of eradication of
MRSA colonization in general (non-CF) populations evaluated six clinical trials and
concluded not only insufficient data around eradication efficacy but also a high rate
of adverse events associated with treatment (20%).[53] Taken together, these data demonstrate that eradication does decrease rates of persistence
and reduce exacerbation frequency—but have not confirmed slower lung disease progression,
likely in part due to recruitment challenges.[49]
[54] This is particularly relevant in MRSA-related outcomes as early CF studies that
were not adequately powered initially failed to demonstrate MRSA's significant potential
for harm.[55]
Haemophilus influenzae
H. influenzae, a gram-negative coccobacillus, is commonly found in the upper respiratory tract
of healthy and ill individuals alike—but recovery from the lower airways in pwCF is
thought to indicate disease as its presence is associated with local inflammation.[56]
[57]
H. influenzae is the second most prevalent species (approximately 28%) in the first 5 years of
life of pwCF—with similar rates into early adolescence before declining to approximately
10% in adulthood.[58]
H. influenzae possesses several adherence factors that contribute to bacterial colonization, persistence,
and biofilm formation.[59] Nonencapsulated H. influenzae are most commonly identified in pwCF including those associated with PEx.[15]
[60] Unique relative to other CF pathogens, strains of H. influenzae causing infections in pwCF are usually transient in airways with persistent infection
over years by a single strain occurring only in a minority of cases.[61]
H. influenzae from pwCF have the ability to become resistant to several classes of antibiotics
([Table 1]), driven in part by hypermutability phenotypic adaptation.[61]
[62] While the clinical implications of H. influenzae isolation are less clear, a retrospective longitudinal study of 349 patients over
15 years (1998–2012) indicated a doubling in prevalence (8–16%, p < 0.0001; mean age 7.6 years) over the study period, suggesting this is likely becoming
a greater cause of infection in younger pwCF.[63] Given the high turnover of H. influenzae strains within the CF airways, studies examining the potential impact of early confirmed
culture-directed therapy are lacking, and the practice of treatment (vs. observation)
is currently clinician dependent.
Pseudomonas aeruginosa
P. aeruginosa, a gram-negative bacillus, is historically the most prevalent (approximately 60–80%)
pathogen in adult pwCF. The increasing prevalence of P. aeruginosa in adolescence and young adulthood is felt to be driven by both bacterial exposure
and recurrent antibiotic courses from the eradication of early airway colonizers.[64] Using data from several national CF patient registries ([Fig. 2]), a significant rise in P. aeruginosa prevalence can be observed between those 6 to 10 years and those 18 to 24. Concurrently,
the prevalence of both H. influenzae and S. aureus decreases in parallel with increases in P. aeruginosa, further depicting dynamic longitudinal shifts among the classical pathogens.[65]
P. aeruginosa is ubiquitous in the local soil and aquatic environment, thus ensuring exposure from
a range of sources.[66] Historically, it was perceived that P. aeruginosa strains were unique to each individual CF patient and that for transmission to occur,
repeated and close contact was required (i.e., such as that exhibited in the same
household or between siblings).[66] However, our understanding of transmission has expanded with the recognition of
several epidemic strains passed exclusively from pwCF to pwCF (i.e., the transcontinental
Liverpool epidemic strain), many of whose infection is associated with worse outcomes.[66]
[67] Once acquired chronically, pwCF typically harbor strains that rapidly evolve through
several adaptive mechanisms, including the acquisition of mutations. One such example
is the transition from nonmucoid to mucoid phenotype, which is associated with fitness
advantages and consequent accelerated clinical deterioration.[68]
[69]
The natural history of incident P. aeruginosa acquisition is such that infections may evolve into chronic infection whereby a specific
strain recovered by culture is observed with increasing frequency before eventually
being identified.[70] While multiple definitions of chronic infection exist,[71] the most commonly used is the Leeds criteria[72] (i.e., isolation of P. aeruginosa in >50% of sputum cultures over a 12-month period). Development of chronic P. aeruginosa has significant adverse clinical impacts including worse baseline ppFEV1,[66]
[73]
[74]
[75] accelerated lung function decline,[74]
[76]
[77] worse radiographic and symptom scores,[78]
[79] lower nutritional status,[80] and faster progression to end-stage lung disease and death[77]
[81]
[82]
[83]
[84] compared to those pwCF without P. aeruginosa. Moreover, children colonized with P. aeruginosa have on average a 10-year reduced survival compared to those patients without P. aeruginosa infection.[85]
Traditional dogma once held that P. aeruginosa chronic airway infection was an inevitable consequence of disease progression; however,
it is now understood that early and aggressive antibacterial eradication protocols
may abrogate P. aeruginosa's potential to cause chronic infection until further into adulthood (and potentially
indefinitely).[66]
[86] A wide range of P. aeruginosa early eradication protocols have been developed and assessed for efficacy relative
to historical controls. Because of this compelling evidence base, early eradication—in
one form or another—has become the standard of care without a placebo-controlled randomized
study having ever been performed.[87]
[88]
[89] Indeed, early eradications are largely credited with the tremendous drop in P. aeruginosa prevalence observed in recent cohorts ([Fig. 2]). Accordingly, guidelines recommend serial airway surveillance and prompt eradication
in response to new P. aeruginosa acquisition with inhaled antibiotic regimens that include tobramycin, colistin, and/or
aztreonam ([Table 1]); however, optimal regimens are continually being explored.[90] The Early Pseudomonas Infection Control (EPIC) study found no additional benefit to oral ciprofloxacin
in addition to nebulized high-dose tobramycin relative to tobramycin alone over 28
days.[88] Similarly, extending treatment with tobramycin over 56 days conferred no additional
benefit in the ELITE study.[87] The recent Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis (TORPEDO-CF) sought to evaluate the addition of 14
days of ceftazidime/tobramycin or 12 weeks of oral ciprofloxacin in combination with
12 weeks of nebulized colistin. Although there were fewer hospitalized patients in
the intravenous group during follow-up, the authors' concluded outcomes were not different.[91] While antipseudomonal prophylaxis is not currently recommended following successful
eradication (given the observation that secondary cycled prophylactic antipseudomonal
antibiotic therapy offers no advantage over culture-based treatment), clinical uncertainty
exists with the repeat isolation of P. aeruginosa—where this may represent a new infection or initial failure of eradication.[66] When possible, management strategies may be informed with the use of isolate genotyping
to discern incident versus persistent strain status.[66] Novel, incremental eradication strategies that seek to sequentially manage initial
failures with increasingly aggressive regimens are increasingly being invoked.[92]
[93]
While prevention of chronic infection is felt to ameliorate adverse clinical outcomes,
the evidence this provides a durable clinical benefit is less convincing. Mayer-Hamblett
and colleagues evaluated long-term efficacy over 5 years in a cohort of pediatric
subjects in the EPIC study who received eradicative therapy for newly acquired P. aeruginosa. While those who achieved sustained eradication throughout the trial had a reduced
risk of developing chronic P. aeruginosa, mucoid phenotype detection, and less antipseudomonal antibiotics, there was no significant
association in the rate of PEx or lung-function decline—suggesting microbiologic outcomes
may not directly translate to clinical response.[94] Alternatively, this may demonstrate the durability of chronic suppressive antipseudomonal
therapies. Indeed, many of the gains achieved in CF outcomes prior to the HEMT era
directly relate to the potency and efficacy of antipseudomonal suppression developed
through dedicated clinical studies.[95]
[96]
[97]
[98] A discussion on the strategies, regimens, and drugs used for the acute and longitudinal
management of chronic of P. aeruginosa is well beyond the scope of this review. Indeed, lessons derived from P. aeruginosa have now been applied to other pathogens in pwCF and other chronic lung diseases
(i.e., non-CF bronchiectasis, NCFB).
Burkholderia cepacia Complex
The B. cepacia complex (Bcc) consists of over 20 closely related species[15] with the two most commonly identified in CF being B. cenocepacia and B. multivorans. While these species are lumped together based on bacteriologic features, the clinical
impact of these different species is often profoundly different.[31] While the prevalence of Bcc is generally reported as 5 to 10% of pwCF ([Fig. 2]), a recent Canadian study demonstrated profound epidemiological shifts within this
range, with a significant decline in the limited numbers of epidemic B. cenocepacia strains more recently being replaced with the increasing prevalence of nonclonal
isolates of B. multivorans and other species.[99]
B. cenocepacia, in particular, have been associated with more severe lung disease including rapid
respiratory decline and increased overall mortality.[100] While uncommon and very rare in recent years, rapidly progressive necrotizing pneumonia
with or without refractory bacteremia termed “cepacia syndrome” from (predominately)
B. cenocepacia has been associated with near-uniform fatality.[11] Those pwCF with Bcc infections prior to lung transplant are more likely to result
in rapid decline and experience higher mortality following lung transplant, with infection
often precluding transplant listing in all but the most experienced centers.[101] Recognized even prior to P. aeruginosa, patient-to-patient transmission of epidemic clones of B. cenocepacia (in particular ET-12) and B. dolosa has been one of the driving forces behind the advancement of infection and prevention
control measures to prevent the spread.[102]
[103]
[104] Given the adverse outcomes associated with many Bcc chronic infections, there is
great interest in extrapolating early eradication learnings. Owing to low incidence,
currently, there are no uniform practice guidelines around eradication in response
to early isolation.[31]
[105]
[106] Antibiotic therapy for Bcc is even more complicated than P. aeruginosa and limited by the high level of intrinsic and easily acquired antibiotic resistance,
leaving few therapeutic options ([Table 1]).
Stenotrophomonas maltophilia
Stenotrophomonas maltophilia is a gram-negative bacteria with inherent multidrug resistance that has increasingly
emerged over the last few decades as pwCF are living longer—with prevalence rates
ranging from 8 to 14% of adults.[107] Infection with S. maltophilia disproportionally occurs in those with more advanced disease and those who experience
more exaggerated rates of lung function decline.[108]
[109] While some speculate that the presence of S. maltophilia may simply represent colonization without directly impacting long-term lung function
or survival,[108]
[110] a large cross-sectional cohort study of pwCF using serum antibody levels demonstrated
that chronic infection was an independent risk factor for PEx requiring hospitalization.[111] Notably, the association of chronic S. maltophilia infection as a risk factor for hospitalization for PEx remained when adjusted for
other clinical factors including baseline ppFEV1, disease stage, age, and presence of P. aeruginosa. Moreover, there were increased unadjusted rates of mortality and lung transplantation
among those with S. maltophilia infection although the effect was not significant after adjustment using a time-varying
model.[112] More recently, a single-center cohort study identified pwCF and incident acquisition
of S. maltophilia to have a worsening mean annual decline in ppFEV1 (−2.14 vs. −1.67/year) and increased hospitalization rates.[113] A recent Cochrane review found no available randomized control trials in either
the setting of acute PEx or chronic infection to evaluate the effectiveness of antibiotic
therapy against S. maltophilia in pwCF.[107] There are currently no consensus guidence statements regarding treatment or eradication
strategies. Given this lack of evidence, the current mainstay of management is determined
by clinical experience with the field uniformly acknowledging a desperate need for
pragmatic trials.
Achromobacter species
Achromobacter spp. are aerobic, nonfermenting gram-negative bacilli frequently recovered from environmental
resevoirs.[114] Variations in center-to-center reported prevalence are significant and likely reflect
varying ability to correctly identify and distinguish from other pathogens such as
P. aeruginosa, infection control, and antibiotic usage.[115]
[116] While infections were historically attributed exclusively to Achromobacter xylosoxidans, we now recognize the diversity of Achromobacter species in pwCF—with many species as prevalent as A. xylosoxidans.[117] Similar to P. aeruginosa, Achromobacter. spp possess several intrinsic characteristics enabling survival and potentially contributing
to disease progression including highly dynamic genomes, hypermutation, intrinsic
multidrug resistance, and capability to produce biofilms.[118] The clinical significance of Achromobacter, in particular A. xylosoxidans, has been debated with some early studies demonstrating no differences in lung function
between those colonized and not.[114]
[119] More recently, others have demonstrated pwCF colonized with A. xylosoxidans exhibit accelerated decline in pulmonary function[115]
[120] with decline in ppFEV1 at rates similar to colonization with P. aeruginosa.[121] While most studies evaluating Achromobacter have been done in adults, Sunman et al observed similar findings in children with
CF with significantly greater ppFEV1 decline (−9.07 vs. −1.18/year, p = 0.0043) and number of PEx (4 vs. 3, p = 0.0001) in the infected compared to uninfected group, respectively.[122] Similar to P. aeruginosa and Bcc, clonality and potential transmission of Achromobacter between pwCF have been suspected.[114] Currently, there is no evidence to provide guidance on whether eradication may abrogate
chronic infection and no standard eradication protocols exist. The role of additional
inhaled antibiotics in systemic therapy in Achromobacter eradication is not definitively established, although one study showed 56% of patients
who received inhalation therapy (ceftazidime, colistin, or tobramycin) remained colonization-free
after 3 years compared to 13% of patients without treatment.[123] Early studies evaluating cefiderocol, a newer generation parenteral siderophore-linked
cephalosporin,[124] have shown some promise toward eradication in small cohorts[125]
[126] but long-term efficacy and dosage in pwCF remain unknown.
Other Cystic Fibrosis Pathogens
While the classical pathogens detailed above and reported in national data registries
remain the most common among pwCF ([Fig. 2]), a range of organisms previously rarely observed (or recognized) have increasingly
been reported (i.e., Chryseobacterium, Inquilinus, Pandoraea, and Ralstonia species).[15] Given the rarity of these species in clinical medicine, they have garnered considerable
attention. In contrast, members of the Enterobacterales (i.e., Escherichia coli and Serratia marcescens) are commonly found in single-center studies but comprehensive efforts to understand
their prevalence in large datasets remain lacking.[127] Hector et al found changing epidemiology patterns of classic pathogens over the
last decade across Europe including decreases in P. aeruginosa and Bcc with subsequent increases in NTM, S. aureus and S. maltophilia.[128] Changes in prevalence are multifactorial and likely reflect improvements in both
clinical care and infection control practice patterns.[105]
[129] Taken together, whether these truly represent “emerging pathogens” only time and
development of longitudinal studies will tell.
Culture-Independent Techniques and the Evolving Landscape of Cystic Fibrosis Airway
Infections
The adoption of culture-independent molecular analysis over the last two decades has
demonstrated complex microbial communities within the airways of pwCF well beyond
those recovered through traditional aerobic culture using a limited number of semiselective
media.[15] This relative “shift” in the understanding of infection in CF, from single host-pathogen
relationship to complex polymicrobial community complete with interspecies competition
and differential host response, has moved to the forefront of CF microbiology. Moreover,
understanding the nuance between colonization and infection is crucial as historically
this distinction was made based on the ability to provoke an inflammatory host response,
and new data demonstrate the complexity of indirect pathogenesis and potential for
antagonism. Pioneering work by Rogers et al[130] and Harris et al[131] first recognized complex communities in CF-derived sputum far beyond that identified
through traditional aerobic culture. Following these studies, a wide range of investigators
using next-generation sequencing have worked to expand our understanding of the CF
airways. A relative “core community” (present in high abundance across a large proportion
of patients) including Streptococcus, Prevotella, Veillonella, Neisseria, and Porphyromonas, has been detected in the majority of adult studies in addition to the classic pathogens
of Pseudomonas and Staphylococcus.[132] However, the breadth of diversity is much greater. Culture-independent methods have
identified 50 to 200 unique operational taxonomic units in individual CF samples (with
the majority representing satellite organisms—present in low abundance and/or in a
minority of individuals). Accordingly, it is now widely accepted that the CF lung
is home to diverse bacterial, fungal, and viral taxa and that these polymicrobial
communities are highly individuated to each patient[17]
[133]
[134]
[135]
[136]
[137]
[138]
[139]
[140]
[141]
[142] such that the same community makeup persist even in pwCF postlung transplantation.[143]
Not surprisingly, the microbial community in advanced CF disease is particularly skewed
with a small number of dominant pathogens that clonally expand to occupy a sizable
proportion of the surrounding niche.[144]
[145]
[146] In contrast, diversity, a measure of species richness and evenness of a community,
is often maintained in patients with stable respiratory function.[17] Multiple studies have established that a pattern of decreasing microbial diversity
is associated with subsequent deterioration in lung function over time[147]
[148]
[149]
[150]
[151]
[152]
[153] counteracted with relative increases in dominant taxa by traditional CF pathogens.[17]
[134]
[154]
[155] For instance, as P. aeruginosa colonization becomes chronic in late adolescence and early adulthood, community richness
and diversity are lost and this associates with disease progression.[17]
[156] Finally, as in any ecosystem, microbes found in the CF lung are linked by dynamic
and complex webs of interactions with dysbiosis allowing new organisms to proliferate
and existing populations to expand.[157]
The CF lung represents a unique ecological niche where mucosal hyperviscosity and
ongoing bacterial proliferation further propagate the development of a heterogenous
oxygen gradient,[158] in part due to diffuse areas of bronchiectasis and mucus plugging.[159]
[160] Consequently, anaerobic bacteria are now recognized as part of the core CF microbiota
including Prevotella, Veillonella, Fusobacterium, Peptostreptococcus, and Porphyromonas.[161]
[162]
[163] Furthermore, many CF pathogens may also function as facultative anaerobes given
hypoxic regions within the airways. While ample studies have clearly established that
these organisms can colonize the airways of patients at cell densities comparable
to classical CF pathogens,[161]
[164]
[165]
[166] if and how they might contribute to disease progression remains controversial. A
large cross-sectional cohort analysis by Zemanick et al identified subjects with a
high proportion of anaerobes within sputum experienced reduced inflammation and improved
lung function compared to those subjects with P. aeruginosa.[167] Using extended bacterial culture methods to assess sputum and bronchoalveolar lavage
specimens from a large cohort of pwCF, Muhlebach et al sought to better delineate
this relationship. Ultimately, both the presence and relative abundance of anaerobes
were associated with milder disease, including improved lung function.[162] While beneficial roles of anaerobes have been postulated, negative associations
have more frequently been reported with several studies demonstrating increased abundance
correlating to PEx.[147]
[148]
[149]
[150]
[168]
[169]
The lower airways should be considered from a polymicrobial perspective with microbe–microbe
and microbe–host interactions. Several animals and in vitro studies have demonstrated microbial interactions contributing to a greater degree
and persistence of infection. For example, the increased virulence potential of P. aeruginosa in response to the presence of previously considered benign commensal microbiota
is partially mediated by the general bacterial signaling molecules AI-2[170]
[171] and 2,3-butanediol.[172] Microbial metabolites produced locally in the airways or from the gut, such as small
chain fatty acids, can affect host responses although there are contradictory data
around the beneficial or harmful response.[173] Although most studies to date have sought interactions that increase the virulence
of CF pathogens, it is expected that antagonistic interactions may occur such as in vitro data demonstrating that several commensal isolates of S. mitis and S. oralis derived from patient sputum can reduce epithelial cell proinflammatory responses
to P. aeruginosa.[174] Recently, Rothia mucilaginosa, commonly found in the oropharyngeal and lower respiratory tract in CF, was found
to have an inhibitory effect on pathogen (i.e., P. aeruginosa, and S. aureus) induced pro-inflammatory responses, both in vitro and in vivo.[175]
How Cystic Fibrosis Transmembrane Conductance Regulator Modulators Can Affect Infections:
Real-World Evidence
The successful introduction of HEMT to a large fraction of the CF population (estimated
>90% in some countries)[176] has been a pivotal milestone in the fight to control and mitigate CF. However, as
airway infections persist (as described below), a great many questions have arisen.
While still in its infancy, several real-world studies provide some early insight
into these issues ([Fig. 4]).
Fig. 4 Mechanisms by which HEMT is proposed to impact microbial communities in the CF airways.
(A), Modulators may have direct antimicrobial properties against pathogens, such as
killing of Staphylococcus aureus and P. aeruginosa. (B) CFTR modulators may synergize with traditional antibiotic therapy, such as those
delivered by chronic nebulization, to disproportionally kill pathogens. (C) Therapy with CFTR modulators leads to decreased bioburden and relative restructuring
of microbiome constituents. (D) Anti-inflammatory properties, whether direct through the modulator therapy itself
or indirect through mechanisms described previously reduce host inflammation. (E) Improved mucus hydration and subsequent mucociliary clearance may improve bacterial
clearance and therefore reduce bioburden within the airways. Figure created with BioRender.
Ivacaftor, targeting the Gly551Asp gating mutation to increase channel time, was the
first available HEMT released in 2012 but available only to a fraction of pwCF.[65] Several outcome measures including ppFEV1, body mass index, and quality of life showed remarkable improvement in clinical trials
for both pediatric (STRIVE) and adult (ENVISION) cohorts. Given these changes, how
do CF pathogens and microbial communities differ following therapy? Heltshe et al
evaluated P. aeruginosa persistence by culture in 151 pwCF and found that 29% of those positive in the year
prior to ivacaftor initiation were culture negative in the year following, while 88%
of those that were P. aeruginosa free in the year prior remained negative,[177] confirming earlier observations of P. aeruginosa burden reduction after 6 months of therapy.[178] Similarly, a retrospective cohort of 275 pwCF on ivacaftor showed a significant
long-term decline in the relative abundance of all classical pathogens, except Bcc.[179] Given most adult pwCF exhibit chronic airway infections, what is the sustainability
of microbial changes observed with HEMT? To address this, Hisert et al assessed a
cohort of 12 pwCF chronically infected with P. aeruginosa, Bcc, and/or S. aureus over 2 years of ivacaftor treatment.[180] All subjects exhibited reduced P. aeruginosa culture abundance in sputum within the first year, with 10-fold declines in colony
forming units (CFUs) seen as early as the first week following therapy. However, CFUs
rebounded by 210 days and none of the subjects exhibited persistently negative cultures
for P. aeruginosa during the study period—indicating eradication did not occur. Moreover, each subject
continued to be infected with the same strain of P. aeruginosa preivacaftor initiation.
Given the changes observed in cultured pathogens, speculation around whether the microbiome
changes have also arisen. Harris et al used 16S rRNA sequencing to measure total and
specific bacterial load from sputum in 31 pwCF pre- and postivacaftor initiation.[181] While ppFEV1 improved over the 6-month study period, there were no significant changes in bacterial
load or diversity following treatment. Einarsson et al investigated a cohort of pwCF
followed prospectively for 12 months with serial sputum samples pre- and postivacaftor.[182] Extended-culture methodology demonstrated higher densities of obligate anaerobic
bacteria, and greater richness and diversity posttreatment; however, no significant
difference in bioburden was observed by qPCR for either total bacterial 16S rRNA or
P. aeruginosa. Culture-independent approaches confirmed significant increases in richness and a
trend toward increased diversity (p = 0.07) following treatment. Moreover, improvement in lung function, richness and
diversity displayed an inverse correlation with inflammatory markers. While this relative
shift toward a “healthier” lung microbiome was observed postvacaftor, the authors
note overall community composition changes were modest.
Approved in 2019, elexacaftor tezacaftor ivacaftor (ETI) is relevant to many pwCF
as it is effective for all those with at least one copy of the F508del CFTR mutation (and other specific rare mutations),[183] accounting for ≥90% of individuals.[184] ETI has demonstrated impressive multifaceted clinical benefits including a median
13% absolute improvement in ppFEV1 and approximately 60% reduction in PEx compared to placebo. Moreover, ETI is superior
when compared to other modulators such as tezacaftor/ivacaftor in head-to-head studies.[185] The first microbiome study completed by Sosinski et al found that diversity and
evenness increased in 24 pwCF (with ≥1 F508del mutation) pre- and post-ETI therapy
but with no specific microbial taxa changes apart from the log-ratio of pathogens
to anaerobes, indicating modest community restructuring.[186] Consistent with almost all other longitudinal studies, the microbiome structure
was more similar within an individual pre- and posttreatment than between subjects
after-modulator initiation.[133]
[187]
Given the findings described above, questions have been raised around the durability
of HEMT-related effects in airway microbiology. To address this, the upcoming PROMISE
(NCT04038047), a large U.S. multidisciplinary prospective study assessing the broad
impacts of long-term ETI therapy in pwCF ≥6 years aims to clarify some of these questions
raised by evaluating both culture-dependent and independent measures of pathogen/microbiome-constituent
abundance.[188] PROMISE will examine nearly 250 subjects with collections of sputum at 1-, 3-, 6-,
12-, and 24-month time points with the goal to define changes in pathogen density
over time by utilizing 16S rRNA gene sequencing and pathogen-targeted quantitative PCR to determine pathogen persistence
and individual microbiomes changes over time.
